Clinical Trial: NCT03739931
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | ModernaTX, Inc. |
| Information Provided By: | ModernaTX, Inc. |
| Last Update Posted: | 2025-08-15 |
Study Overview
Brief Summary
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Official Title
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Intervention / Treatment
- Biological: mRNA-2752
- Biological: Durvalumab
Other Study ID Numbers
- mRNA-2752-P101
- 2022-001597-55
Start Date (Actual)
2018-11-27
Primary Completion Date (Actual)
2025-08-01
Study Completion Date (Actual)
2025-08-01
Enrollment (Actual)
134
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | ModernaTX, Inc. |
| Information Provided By: | ModernaTX, Inc. |
| Last Update Posted: | 2025-08-15 |
Study Overview
Brief Summary
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Official Title
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Intervention / Treatment
- Biological: mRNA-2752
- Biological: Durvalumab
Other Study ID Numbers
- mRNA-2752-P101
- 2022-001597-55
Start Date (Actual)
2018-11-27
Primary Completion Date (Actual)
2025-08-01
Study Completion Date (Actual)
2025-08-01
Enrollment (Actual)
134
Study Type
Interventional
Phase
Phase 1